Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ALX Oncology Holdings Inc. - Common Stock (NQ: ALXO ) 1.830 UNCHANGED Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 143 Open 1.830 Bid (Size) 1.760 (1) Ask (Size) 1.870 (10) Prev. Close 1.830 Today's Range 1.830 - 1.830 52wk Range 1.190 - 17.82 Shares Outstanding 40,869,135 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium December 18, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 December 12, 2024 From ALX Oncology Via GlobeNewswire Performance YTD -87.42% -87.42% 1 Month +24.49% +24.49% 3 Month +1.10% +1.10% 6 Month -68.88% -68.88% 1 Year -87.87% -87.87% More News Read More ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer December 10, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference November 26, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer November 14, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 07, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Announces November Investor Conference Participation November 04, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 November 01, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference September 09, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi September 04, 2024 From ALX Oncology Via GlobeNewswire Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month August 27, 2024 Via Benzinga ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024 August 09, 2024 Via InvestorPlace ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 08, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors August 06, 2024 From ALX Oncology Via GlobeNewswire Crude Oil Moves Lower; Moderna Shares Plunge August 01, 2024 Via Benzinga Exposures Fossil Fuels Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July August 01, 2024 Via Benzinga Topics Stocks Exposures US Equities Nasdaq Surges 1%; Meta Posts Upbeat Earnings August 01, 2024 Via Benzinga Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients August 01, 2024 Via Benzinga Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket August 01, 2024 Via Benzinga ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer July 31, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer July 31, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer June 02, 2024 From ALX Oncology Via GlobeNewswire ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference May 29, 2024 From ALX Oncology Via GlobeNewswire ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 May 09, 2024 Via InvestorPlace ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From ALX Oncology Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
